
<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <link rel="stylesheet" href="../style.css">
    <title>Document</title>
</head>
<body>

<span class="table_title">False Negatives</span>

<table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th></th>
      <th>generated</th>
      <th>gold</th>
      <th>text</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <th>39</th>
      <td></td>
      <td>4.5 mg/200 g BW</td>
      <td>daily for two weeks at morning and a single captopril dose (4.5 mg/200 g BW; p.o.)</td>
    </tr>
    <tr>
      <th>52</th>
      <td></td>
      <td>5 ppm</td>
      <td>For the refined quantified dry extract, the ginkgolic acid content is limited to 5 ppm [154].</td>
    </tr>
    <tr>
      <th>36</th>
      <td></td>
      <td>25 mg/kg)</td>
      <td>Group I and II were orally administered with normal saline for 7 days and Group II was orally administered DAS (25 mg/kg) on the 7th day.</td>
    </tr>
    <tr>
      <th>51</th>
      <td></td>
      <td>500 mg</td>
      <td>Another patient experienced liver injury after taking 500 mg leaf powder every 2–3 days as a laxative [117].</td>
    </tr>
    <tr>
      <th>18</th>
      <td></td>
      <td>38 mg/kg bw</td>
      <td>Haloperidol (38 mg/kg bw) was applied intramuscularly once every 4 weeks over 12 weeks beginning after 15 days of treatment with valerian [51].</td>
    </tr>
    <tr>
      <th>0</th>
      <td></td>
      <td>1%<br>200 μL<br>10%</td>
      <td>Radio labeled digoxin [ Parental and transfected MDCK-II cells were grown in DMEM supplemented with 10% FBS, 1% non-essential amino acids, 1%  The assay for reversible inhibition was conducted in a total volume of 200 μL in 96-well microplates.</td>
    </tr>
    <tr>
      <th>17</th>
      <td></td>
      <td>500 mg</td>
      <td>Daily before going to bed, participants took two tablets, with 500 mg valerian extract each (extraction solvent ethanol 70%, valerenic acid content 5.51 mg/tablet), for 14 subsequent days.</td>
    </tr>
    <tr>
      <th>11</th>
      <td>1000 mg × 4 times a day<br>7680 mg<br>1000 once a day</td>
      <td>1000 mg<br>7680 mg</td>
      <td>AAP at 1000 once a day or 1000 mg × 4 times a day was administered in the presence or absence of GGT (7680 mg) daily.</td>
    </tr>
    <tr>
      <th>43</th>
      <td></td>
      <td>6 g</td>
      <td>However, a daily Gouqizi dose of 6 g (dosing recommended by Chinese Pharmacopoeia) for 3 days did not enhance the effects of warfarin in three patients with prosthetic heart values who were concomitantly taking warfarin.</td>
    </tr>
    <tr>
      <th>40</th>
      <td></td>
      <td>6</td>
      <td>(n = 6).</td>
    </tr>
    <tr>
      <th>34</th>
      <td></td>
      <td>2 × 10</td>
      <td>Briefly, 2 × 10 Total RNA was extracted from the cells using the Trizol (CW0581, CWbio, Beijing, China).</td>
    </tr>
    <tr>
      <th>28</th>
      <td>120 mg</td>
      <td>120 mg</td>
      <td>Administration of EGb 761® 120 mg b.i.d.</td>
    </tr>
    <tr>
      <th>15</th>
      <td></td>
      <td>10 mg</td>
      <td>(2007) concluded that there were no pharmacodynamic interactions between warfarin and cranberry juice, but they employed a low dose of warfarin (10 mg), which made this end point difficult to assess.</td>
    </tr>
    <tr>
      <th>12</th>
      <td></td>
      <td>1,200 mg</td>
      <td>In Stage 2 77 additional participants were randomized to either 1,200 mg S. frutescens or placebo.</td>
    </tr>
    <tr>
      <th>55</th>
      <td>25 μg/ml</td>
      <td>25 μg/ml</td>
      <td>The activation was highest at 25 μg/ml concentration.</td>
    </tr>
    <tr>
      <th>9</th>
      <td></td>
      <td>1000 mg<br>7680 mg</td>
      <td>Therefore, two simulation scenarios were used to evaluate the magnitude of any interaction, (AAP 1000 mg once daily + GGT 7680 mg once daily) and (AAP 1000 mg × 4 times daily + GGT 7680 mg once daily) in a week.</td>
    </tr>
    <tr>
      <th>41</th>
      <td></td>
      <td>1.7–2.5<br>1.875 mg</td>
      <td>The patient was compliant regarding the attendance of appointments and in taking the medication, and maintained a therapeutic INR (1.7–2.5) on a maintenance daily dose of 1.875 mg warfarin with monthly INR monitoring.</td>
    </tr>
    <tr>
      <th>44</th>
      <td></td>
      <td>0.2 mg/kg<br>240 or 480 mg/kg</td>
      <td>Sixty Sprague–Dawley rats were used to investigate the effects of warfarin (0.2 mg/kg), Danshen (240 or 480 mg/kg) and Gegen (240 or 480 mg/kg) both in isolation and combination.</td>
    </tr>
    <tr>
      <th>37</th>
      <td></td>
      <td>40 mg/kg</td>
      <td>on the 7th day, 2 h after APG 40 mg/kg administration, and Group IV was administered with APG 40 mg/kg for 7 days.</td>
    </tr>
    <tr>
      <th>19</th>
      <td></td>
      <td>1000 mg<br>600 mg</td>
      <td>Subjects also received rifampin (600 mg) and clarithromycin (1000 mg) for 7 days as positive controls for CYP3A induction and inhibition, respectively.</td>
    </tr>
    <tr>
      <th>16</th>
      <td>600 mg</td>
      <td>600 mg</td>
      <td>Recommended daily doses of valerian root extracts are about 600 mg, usually taken as capsules or tablets.</td>
    </tr>
    <tr>
      <th>26</th>
      <td>8 days<br>240 mg<br>120 mg<br>twice daily</td>
      <td>120 mg<br>240 mg</td>
      <td>The following treatments were administered for 8 days each: placebo twice daily (treatment A), EGb 761® 120 mg twice daily (treatment B), and EGb 761® 240 mg in the morning and placebo in the evening (treatment C).</td>
    </tr>
    <tr>
      <th>29</th>
      <td></td>
      <td>more than 37 seconds<br>greater than seven<br>more than 70 seconds</td>
      <td>At the time of admission to ED, she had a prothrombin time (PT) of more than 37 seconds, activated partial thromboplastin time (aPTT) more than 70 seconds, and international normalized ratio (INR) greater than seven.</td>
    </tr>
    <tr>
      <th>5</th>
      <td></td>
      <td>330 µg/ml<br>> 1000 µg/ml</td>
      <td>The strongest reversible inhibition was against CYP2C9 (IC50 330 µg/ml), and the least inhibition was against CYP1A2 and CYP2B6 (IC50 > 1000 µg/ml).</td>
    </tr>
    <tr>
      <th>49</th>
      <td></td>
      <td>74.27 µmol/L</td>
      <td>At that time the serum creatinine level was 74.27 µmol/L and was stable.</td>
    </tr>
    <tr>
      <th>35</th>
      <td></td>
      <td>25 mg/kg</td>
      <td>The radical alteration in the pharmacokinetic parameters of DAS 25 mg/kg P.O.</td>
    </tr>
    <tr>
      <th>24</th>
      <td></td>
      <td>498</td>
      <td>The median CD4+ T-cell count was 498 (range, 244 to 962) cells/mm3.</td>
    </tr>
    <tr>
      <th>46</th>
      <td></td>
      <td>500 mg</td>
      <td>The selected volunteers were randomized to placebo (inert substitute for a treatment or intervention) or MenoAct851 formulation (500 mg BID for 14 days in double-blind fashion) groups.</td>
    </tr>
    <tr>
      <th>7</th>
      <td></td>
      <td>3 mg/kg<br>5 mg/kg</td>
      <td>Each rat in the combination group received a mixture of fimasartan (3 mg/kg), amlodipine (5 mg/kg), and hydrochlorothiazide (5 mg/kg) dissolved in saline containing 10% DMSO.</td>
    </tr>
    <tr>
      <th>32</th>
      <td></td>
      <td>68 µg/mL<br>150 µg/mL</td>
      <td>There was no significant difference between BNPP (68 µg/mL) and PNS (150 µg/mL).</td>
    </tr>
    <tr>
      <th>21</th>
      <td>160/100 mmHg<br>180 mg/dL</td>
      <td>180 mg/dL<br>160/100 mmHg</td>
      <td>Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone–related cancers; 4) women with uncontrolled hypertension (160/100 mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180 mg/dL or higher, or cases of starting or changing medication due to diabetes within 3 mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1 yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4 wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4 wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4 wk; 12) women who were administered female hormone formulations within 6 mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10 h) within 3 mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1 mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study.</td>
    </tr>
    <tr>
      <th>38</th>
      <td></td>
      <td>5 mg</td>
      <td>5 mg (VAEM, host tree Malus domestica, Lot 7054/0, total mistletoe lectin concentration 306 ng/mL), and Iscador Qu spec.</td>
    </tr>
    <tr>
      <th>53</th>
      <td>7.5<br>28%<br>15</td>
      <td>between 7.5 and 15 mg<br>+28%</td>
      <td>With MTX doses between 7.5 and 15 mg weekly, this effect is moderate (AUC +28% with ASA, less for the others), and there is inter-individual variability.</td>
    </tr>
    <tr>
      <th>47</th>
      <td>100 μg/mL<br>500 μg/mL</td>
      <td>500 μg/mL<br>100 μg/mL</td>
      <td>The metabolic inhibition studies performed in rat plasma suggested that all the herbal extracts (500 μg/mL) and all the herbal components (100 μg/mL) could inhibit the hydrolysis of OS in rat plasma, but the % inhibition rate varied between herbs/herbal components.</td>
    </tr>
    <tr>
      <th>13</th>
      <td></td>
      <td>1200 mg<br>1200mg</td>
      <td>With respect to the MOS-HIV, failure differences were found between placebo and 1200 mg, favouring the 1200mg group.</td>
    </tr>
    <tr>
      <th>23</th>
      <td></td>
      <td>0.5–2.0 g/kg</td>
      <td>In case of ginseng interactions, it was reported that no herb–drug interaction between single oral dose of Korean red ginseng extract (RGE) (0.5–2.0 g/kg) and the probe substrates for five cytochrome P450 (CYP) enzymes (i.e., CYP1A2, 2C9, 2C19, 2D6, 3A) in mouse [12].</td>
    </tr>
    <tr>
      <th>3</th>
      <td></td>
      <td>0.1%<br>0.1% (v/v)</td>
      <td>DMSO was added to the CAW-R61J dosing solutions to 0.1% (v/v) such that all treatment conditions contained 0.1% DMSO.</td>
    </tr>
    <tr>
      <th>25</th>
      <td></td>
      <td><50 copies/ml</td>
      <td>No patient reported adverse events during the study, and all maintained an HIV-1 RNA load of <50 copies/ml at the end of the study.</td>
    </tr>
  </tbody>
</table>
<span class="table_title">False Positives</span>

<table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th></th>
      <th>generated</th>
      <th>gold</th>
      <th>text</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <th>54</th>
      <td>12<br>11</td>
      <td></td>
      <td>[11,12] Such an interaction is particularly relevant to elderly patients on anticoagulant therapy.</td>
    </tr>
    <tr>
      <th>103</th>
      <td>Table S4</td>
      <td></td>
      <td>Table S4.</td>
    </tr>
    <tr>
      <th>16</th>
      <td>standard deviation<br>mean</td>
      <td></td>
      <td>Mean\tS.D.</td>
    </tr>
    <tr>
      <th>119</th>
      <td>2000</td>
      <td></td>
      <td>(2000).</td>
    </tr>
    <tr>
      <th>133</th>
      <td>ad libitum</td>
      <td></td>
      <td>Food and water were supplied ad libitum.</td>
    </tr>
    <tr>
      <th>96</th>
      <td>APG pretreatment<br>DAS administration</td>
      <td></td>
      <td>Hepatic (A) and intestinal (B) BCRP/ABCG2 protein expression in rats after DAS administration with or without APG pretreatment.</td>
    </tr>
    <tr>
      <th>85</th>
      <td>the whole experiments</td>
      <td></td>
      <td>conceived and designed the whole experiments.</td>
    </tr>
    <tr>
      <th>105</th>
      <td>Ammonia</td>
      <td></td>
      <td>Ammonia was used during derivatization since the reaction is optimal at basic pH.</td>
    </tr>
    <tr>
      <th>118</th>
      <td>fifty percent</td>
      <td></td>
      <td>Fifty percent inhibitory concentration (IC   where A = log of concentration of aqueous extract of herb in the incubations.</td>
    </tr>
    <tr>
      <th>129</th>
      <td>12 traditional herbs</td>
      <td></td>
      <td>Jaeumkanghwa soup (JEKHT) is a compound composed of 12 traditional herbs (Jung et al., 2010).</td>
    </tr>
    <tr>
      <th>107</th>
      <td>six rats</td>
      <td></td>
      <td>Values expressed as mean ± SEM of six rats.</td>
    </tr>
    <tr>
      <th>39</th>
      <td>150 μL<br>50 μL<br>1 ng/mL</td>
      <td></td>
      <td>For amlodipine analysis, 50 μL aliquots were mixed with 150 μL acetonitrile containing 1 ng/mL berberine (IS).</td>
    </tr>
    <tr>
      <th>130</th>
      <td>no specific quantities</td>
      <td></td>
      <td>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</td>
    </tr>
    <tr>
      <th>37</th>
      <td>150 μL<br>1 ng/mL</td>
      <td></td>
      <td>Then, 150 μL acetonitrile containing 1 ng/mL berberine (IS) was added to the reconstituted standard curves.</td>
    </tr>
    <tr>
      <th>82</th>
      <td>2012</td>
      <td></td>
      <td>2012).</td>
    </tr>
    <tr>
      <th>21</th>
      <td>mean ± standard deviation<br>measures<br>dosages<br>drug amounts<br>dosage amounts<br>doses<br>concentrations<br>values<br>drug dosage amounts<br>drug doses<br>drug dosage concentrations<br>drug concentrations<br>results<br>quantities<br>dosage</td>
      <td></td>
      <td>Data shown are the means ± S.D.</td>
    </tr>
    <tr>
      <th>63</th>
      <td>600 mg</td>
      <td>600 mg</td>
      <td>Recommended daily doses of valerian root extracts are about 600 mg, usually taken as capsules or tablets.</td>
    </tr>
    <tr>
      <th>78</th>
      <td>120 mg</td>
      <td>120 mg</td>
      <td>Administration of EGb 761® 120 mg b.i.d.</td>
    </tr>
    <tr>
      <th>6</th>
      <td>42 mg/kg</td>
      <td></td>
      <td>Group one was administered 42 mg·kg Data are presented as mean ± standard deviation (SD).</td>
    </tr>
    <tr>
      <th>12</th>
      <td>maximum plasma concentration</td>
      <td></td>
      <td>The maximum plasma concentration (C Rat liver microsomes were used to determine the metabolic rate of AC.</td>
    </tr>
    <tr>
      <th>72</th>
      <td>0.54–1.32 pg/mL</td>
      <td></td>
      <td>A 1,1′,3,3′-tetramethoxypropane was used to construct the calibration curve as the standard [32] (reference value: 0.54–1.32 pg/mL).</td>
    </tr>
    <tr>
      <th>89</th>
      <td>5500 V<br>500°C</td>
      <td></td>
      <td>The TurboIonSpray interface was operated in positive ion mode at 5500 V and 500°C.</td>
    </tr>
    <tr>
      <th>61</th>
      <td>population PKPD parameter estimates</td>
      <td></td>
      <td>Pharmacokinetic–pharmacodynamic modelling  The population PKPD parameter estimates for warfarin are presented in the Table 3.</td>
    </tr>
    <tr>
      <th>125</th>
      <td>100 μg/mL<br>500 μg/mL</td>
      <td>500 μg/mL<br>100 μg/mL</td>
      <td>The metabolic inhibition studies performed in rat plasma suggested that all the herbal extracts (500 μg/mL) and all the herbal components (100 μg/mL) could inhibit the hydrolysis of OS in rat plasma, but the % inhibition rate varied between herbs/herbal components.</td>
    </tr>
    <tr>
      <th>134</th>
      <td>n = 6<br>mean ± S. D.</td>
      <td></td>
      <td>Data are expressed as mean ± S. D. (n = 6).</td>
    </tr>
    <tr>
      <th>49</th>
      <td>1000 mg × 4 times a day<br>7680 mg<br>1000 once a day</td>
      <td>1000 mg<br>7680 mg</td>
      <td>AAP at 1000 once a day or 1000 mg × 4 times a day was administered in the presence or absence of GGT (7680 mg) daily.</td>
    </tr>
    <tr>
      <th>42</th>
      <td>five<br>CV<br>six<br>independent experiments<br>mean</td>
      <td></td>
      <td>Data represented as mean and CV from five or six independent experiments.</td>
    </tr>
    <tr>
      <th>47</th>
      <td>1000 mg<br>1000 mg × 4 times<br>8 tablets</td>
      <td>1000 mg</td>
      <td>To mimic the recommended dose based on the status of patients, AAP dose is suggested from 1000 mg to the maximum dose of 1000 mg × 4 times (8 tablets) per day for treatment of the common cold [22,23].</td>
    </tr>
    <tr>
      <th>115</th>
      <td>7.2</td>
      <td></td>
      <td>7.2.</td>
    </tr>
    <tr>
      <th>13</th>
      <td>1<br>500<br>ng/mL</td>
      <td></td>
      <td>Linearity for AC was obtained over the concentration range of 1–500 ng/mL.</td>
    </tr>
    <tr>
      <th>154</th>
      <td>25 μg/ml</td>
      <td>25 μg/ml</td>
      <td>The activation was highest at 25 μg/ml concentration.</td>
    </tr>
    <tr>
      <th>122</th>
      <td>P<br>S4</td>
      <td></td>
      <td>S4, the P The above in-vitro experiments suggested that there should be some potential HDI between OS and these anti-influenza herbs/herbal components during absorption and metabolism.</td>
    </tr>
    <tr>
      <th>127</th>
      <td>absolute z-score<br>level of HDI relevancy</td>
      <td></td>
      <td>After such a normalization, the absolute z-score of an herb/herbal component effect on OS would be proportional to its level of HDI relevancy with OS.</td>
    </tr>
    <tr>
      <th>74</th>
      <td>8 days<br>240 mg<br>120 mg<br>twice daily</td>
      <td>120 mg<br>240 mg</td>
      <td>The following treatments were administered for 8 days each: placebo twice daily (treatment A), EGb 761® 120 mg twice daily (treatment B), and EGb 761® 240 mg in the morning and placebo in the evening (treatment C).</td>
    </tr>
    <tr>
      <th>91</th>
      <td>0.05<br>66.77%<br>41.06%</td>
      <td></td>
      <td>The APG-pretreated rats showed significant inhibition of the BCPR/ABCG2 protein that is (66.77% and 41.06% inhibition, respectively) as compared to DAS only (p < 0.05).</td>
    </tr>
    <tr>
      <th>104</th>
      <td>1.0 mL</td>
      <td></td>
      <td>The loss of body fluid was compensated by administrating 1.0 mL saline solution (p.o.)</td>
    </tr>
    <tr>
      <th>84</th>
      <td>22 compounds</td>
      <td></td>
      <td>A total of 22 compounds were identified or tentatively identified (Figure 1).</td>
    </tr>
    <tr>
      <th>36</th>
      <td>triplicate determinations</td>
      <td></td>
      <td>of triplicate determinations.</td>
    </tr>
    <tr>
      <th>2</th>
      <td>50 μl<br>20 μl<br>250 ng<br>2.5 × HotMasterMix</td>
      <td></td>
      <td>Briefly, PCR was performed in a final reaction volume of 50 μl, which included 20 μl 2.5 × HotMasterMix (Eppendorf, Westbury, NY, USA), approximately 250 ng of human genomic DNA and the primer pairs (0.25 μM).</td>
    </tr>
    <tr>
      <th>131</th>
      <td>13.3<br>15.00</td>
      <td></td>
      <td>However, the total AUC for CHO was lower in YM than PLC (13.3 vs. 15.00, p < 0.001).</td>
    </tr>
    <tr>
      <th>58</th>
      <td>9%</td>
      <td></td>
      <td>The AUC0–∞ of quinine was slightly reduced by about 9 %.</td>
    </tr>
    <tr>
      <th>80</th>
      <td>unclear risk of bias<br>high risk of bias</td>
      <td></td>
      <td>marked circle, Unclear risk of bias; Minus (-) marked circle, High risk of bias.</td>
    </tr>
    <tr>
      <th>117</th>
      <td>quantities</td>
      <td></td>
      <td>Competing interests          The authors have declared no conflicts of interests.</td>
    </tr>
    <tr>
      <th>108</th>
      <td>significantly different<br>p < 0.001</td>
      <td></td>
      <td>*significantly different from normal group, # significantly different from diabetic control group at p < 0.001.</td>
    </tr>
    <tr>
      <th>52</th>
      <td>earlier study</td>
      <td></td>
      <td>This finding also corroborates the results of an earlier study in young individuals.</td>
    </tr>
    <tr>
      <th>98</th>
      <td>60 degrees/second<br>2 min<br>5</td>
      <td></td>
      <td>In the main test session, subjects performed 5 isokinetic knee extensions of the leg at an angular velocity of 60 degrees/second, and subjects recovered passively for 2 min between sets of measurements [26,27].</td>
    </tr>
    <tr>
      <th>57</th>
      <td>5ml</td>
      <td></td>
      <td>Sample collection  Venous blood samples (5ml) was collected into heparinised tubes at time zero (just before the administration of quinine sulphate tablets)) and at 1, 2, 3,4, 6, 8, 12, 24, 36 and 48 h after each participant received quinine alone or concurrently with the scheduled dose of G. kola.</td>
    </tr>
    <tr>
      <th>56</th>
      <td>18</td>
      <td></td>
      <td>[18] Taken together these findings indicate that herb-drug interactions attributable to G. biloba are not the result of phytochemical-mediated effects on CYP isoforms.</td>
    </tr>
    <tr>
      <th>124</th>
      <td>S8</td>
      <td></td>
      <td>S8).</td>
    </tr>
    <tr>
      <th>149</th>
      <td>7.5<br>28%<br>15</td>
      <td>between 7.5 and 15 mg<br>+28%</td>
      <td>With MTX doses between 7.5 and 15 mg weekly, this effect is moderate (AUC +28% with ASA, less for the others), and there is inter-individual variability.</td>
    </tr>
    <tr>
      <th>94</th>
      <td>quantities</td>
      <td></td>
      <td>; supervision, K.M.A.</td>
    </tr>
    <tr>
      <th>95</th>
      <td>described entities</td>
      <td></td>
      <td>All authors have read and agreed to the published version of the manuscript.</td>
    </tr>
    <tr>
      <th>116</th>
      <td>MBI</td>
      <td></td>
      <td>MBI, mechanism‐based inhibition Go to: 4.</td>
    </tr>
    <tr>
      <th>83</th>
      <td>approximatly 15 min</td>
      <td></td>
      <td>After administration, aspirin is rapidly hydrolyzed in the body with an elimination half-life of approximatly 15 min [11,12].</td>
    </tr>
    <tr>
      <th>66</th>
      <td>160/100 mmHg<br>180 mg/dL</td>
      <td>180 mg/dL<br>160/100 mmHg</td>
      <td>Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone–related cancers; 4) women with uncontrolled hypertension (160/100 mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180 mg/dL or higher, or cases of starting or changing medication due to diabetes within 3 mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1 yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4 wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4 wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4 wk; 12) women who were administered female hormone formulations within 6 mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10 h) within 3 mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1 mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study.</td>
    </tr>
    <tr>
      <th>110</th>
      <td>9</td>
      <td></td>
      <td>9, Table 2).</td>
    </tr>
    <tr>
      <th>73</th>
      <td>V05895B</td>
      <td></td>
      <td>V05895B; Arkopharma, Madrid, Spain).</td>
    </tr>
    <tr>
      <th>79</th>
      <td>240-mg<br>1 week</td>
      <td>240-mg</td>
      <td>A maximum exposure was realized with a 240-mg EGb 761® daily dose, and exposure duration was sufficient to eventually induce CYPs, as steady state for EGb 761® components was reached, and 1 week is typically sufficient to achieve full induction [35].</td>
    </tr>
    <tr>
      <th>87</th>
      <td>p < 0.01<br>p < 0.05</td>
      <td></td>
      <td>* p < 0.05, ** p < 0.01.</td>
    </tr>
    <tr>
      <th>20</th>
      <td>P</td>
      <td></td>
      <td>***P < 0.0001.</td>
    </tr>
    <tr>
      <th>51</th>
      <td>45</td>
      <td></td>
      <td>[45] Go to: RESULTS General Experimental Observations  All subjects completed the study and no serious adverse events occurred during the course of the investigation.</td>
    </tr>
    <tr>
      <th>114</th>
      <td>high relative quantities</td>
      <td></td>
      <td>Anthocyanins, particularly delphinidin-3-sambubioside and cyanidin-3-sambubioside, are generally believed to be the active constituents responsible for the antihypertensive, antioxidant, and hypocholesterolemic effects of HS, possibly because they are found in high relative quantities in aqueous extracts [8, 11, 13, 16].</td>
    </tr>
    <tr>
      <th>0</th>
      <td>complete normalization</td>
      <td></td>
      <td>Progressive mobilization of the patient was obtained as well as a complete normalization of the laboratory findings.</td>
    </tr>
    <tr>
      <th>7</th>
      <td>±15%</td>
      <td></td>
      <td>The diluted samples were analyzed using a calibration curve to derive their integrities, which were within the acceptable limit of ±15%.</td>
    </tr>
    <tr>
      <th>120</th>
      <td>34860-2.5L-R</td>
      <td></td>
      <td>34860-2.5L-R) and ammonium acetate (catalog No.</td>
    </tr>
    <tr>
      <th>101</th>
      <td>[124]<br>[104]</td>
      <td></td>
      <td>In addition, the enhancement of the antitumor effect was shown to be achieved via the inhibition of tumor cell angiogenesis [104] or increase in the reactive oxygen species production [124].</td>
    </tr>
    <tr>
      <th>65</th>
      <td>Nenhum</td>
      <td></td>
      <td>Apoio financeiro: Nenhum.</td>
    </tr>
    <tr>
      <th>153</th>
      <td>98</td>
      <td></td>
      <td>no interaction [98].</td>
    </tr>
    <tr>
      <th>148</th>
      <td>135</td>
      <td></td>
      <td>This is debated, and there are hints to possible beneficial effects [135].</td>
    </tr>
    <tr>
      <th>86</th>
      <td>described previously</td>
      <td></td>
      <td>Data were evaluated as described previously [28].</td>
    </tr>
    <tr>
      <th>1</th>
      <td>numerous</td>
      <td></td>
      <td>Numerous factors can explain discrepancies between study results such as pain models, healthy subjects vs. patients, routes of administration (inhalation vs. oral), and sources of the product [19,20,21].</td>
    </tr>
    <tr>
      <th>68</th>
      <td>34.1 μM<br>7.8 μM<br>0.1–0.2%<br>0.4–0.5%</td>
      <td></td>
      <td>The plasma concentration was ranged from 7.8 μM to 34.1 μM but unbound fraction of tri-glycosylated PPD-type ginsenosides (Rb1, Rb2, and Rc) was very low (0.1–0.2% in rat plasma, 0.4–0.5% in rat liver; Figure 9B).</td>
    </tr>
    <tr>
      <th>136</th>
      <td>1 mg<br>50 mg<br>1 mcg<br>10 mg<br>200 mg<br>500 mcg<br>2 mcg<br>5 mg<br>5 mcg<br>100 mg<br>20 mg<br>2 mg</td>
      <td></td>
      <td>et Zucc.)</td>
    </tr>
    <tr>
      <th>121</th>
      <td>half-maximal inhibitory concentration</td>
      <td></td>
      <td>The following formula determines the half-maximal inhibitory concentration (IC SRM Medical College Hospital and Research Centre and SRM Institute of Science and Technology, Kattankulathur ethics committees approved the protocol (approval No.</td>
    </tr>
    <tr>
      <th>62</th>
      <td>10, 12</td>
      <td></td>
      <td>It therefore was recommended that they should be avoided in the elderly [10, 12].</td>
    </tr>
    <tr>
      <th>152</th>
      <td>two millennia</td>
      <td></td>
      <td>This herb has been in use for diabetic treatment for almost two millennia [72].</td>
    </tr>
    <tr>
      <th>113</th>
      <td>indomethacin</td>
      <td></td>
      <td>Therefore, the protective effect of A. officinarum on indomethacin-induced gastric injury might also be through the changes of pharmacokinetics for indomethacin and its metabolites to exert.</td>
    </tr>
    <tr>
      <th>60</th>
      <td>27</td>
      <td></td>
      <td>[27] In the study performed by Roozbeh et al.</td>
    </tr>
    <tr>
      <th>8</th>
      <td>10 mg/mL</td>
      <td></td>
      <td>Stock solutions (10 mg/mL) were prepared by diluting the extracts and compounds in distilled water.</td>
    </tr>
    <tr>
      <th>11</th>
      <td>100 mg</td>
      <td></td>
      <td>Briefly, total protein was obtained by homogenizing 100 mg of liver samples with equal volume of a tissue lysis buffer.</td>
    </tr>
    <tr>
      <th>106</th>
      <td>2016</td>
      <td></td>
      <td>2016).</td>
    </tr>
    <tr>
      <th>53</th>
      <td>42</td>
      <td></td>
      <td>[42] The difference in extent of inhibition between the two age groups hints at either an age-related diminution in CYP2E1 responsivity or a dissimilarity in allyl sulfide content between the garlic supplements.</td>
    </tr>
    <tr>
      <th>9</th>
      <td>mean ± SD<br>ratios</td>
      <td></td>
      <td>Relationship between the catechin AUC Abbreviations: AUC Subject baseline characteristics at the start of the study Note: Data are presented as mean ± SD for continuous variables and as ratios for categorical variables.</td>
    </tr>
    <tr>
      <th>64</th>
      <td>toda quantidade</td>
      <td></td>
      <td>Os parâmetros renais e hepáticos, as proteínas do complemento e o sedimento urinário estavam todos normais.</td>
    </tr>
    <tr>
      <th>59</th>
      <td>quantities found in text</td>
      <td></td>
      <td>This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.</td>
    </tr>
  </tbody>
</table>

</body>
</html>
